Daptomycin
Based on 26 publication(s) in Google Scholar
Daptomycin is a lipopeptide antibiotic with rapid in vitro bactericidal activity against gram-positive organisms.
For research use only. We do not sell to patients.
- Purity: 99.55%
- CAS No.: 103060-53-3
- Formula: C72H101N17O26
- Molecular Weight:1620.67
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Daptomycin
More- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Virulence. 2024 Dec;15(1):2415952. [Abstract]
- mBio. 2025 Sep 30:e0212425. [Abstract]
- Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01275-20. [Abstract]
- ACS Omega. 2023 Feb 3;8(6):5415-5425. [Abstract]
- ACS Omega. 2022 Mar 3;7(10):9004-9014. [Abstract]
- Appl Microbiol Biotechnol. 2022 Apr;106(7):2689-2702. [Abstract]
- Microorganisms. 2026 Jun 13;14(6):1332. [Abstract]
- iScience. 2022 Jan 5;25(2):103731. [Abstract]
- Sci Rep. 2025 May 2;15(1):15346. [Abstract]
- Microbiol Spectr. 2025 Oct 23:e0157625. [Abstract]
- ACS Infect Dis. 2025 Jun 13;11(6):1473-1485. [Abstract]
- ACS Infect Dis. 2024 Aug 9;10(8):2961-2977. [Abstract]
- ACS Infect Dis. 2023 Dec 8;9(12):2523-2537. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Infect Drug Resist. 2021 Dec 16;14:5449-5456. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Int J Med Microbiol. 2020 Jan;69(1):120-131. [Abstract]
- Diagn Micr Infec Dis. 2020 Jul;97(3):115040. [Abstract]
- Pol J Microbiol. 2023 Jun 14;72(2):199-208. [Abstract]
- Hong Kong University. 2025.
- bioRxiv. 2025 February 13.
- bioRxiv. 2024 May 10.
- bioRxiv. 2023 Oct 2.
Customer Validation & Images
-
RT-PCR
-
Bio/Physico-chemical Assay
-
Cell Imaging/Staining
-
Bio/Physico-chemical Assay
-
Microbiological Assay
All Antibiotic Isoforms
More
Biological Activity
|
Lipopeptide |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | CC50 |
>100 μM
Compound: Daptomycin
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay
|
[PMID: 30392371] |
| MDCK | EC50 |
0.18 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs in presence of 100 uM verapamil
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs in presence of 100 uM verapamil
|
[PMID: 17548493] |
| MDCK | EC50 |
0.62 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs
|
[PMID: 17548493] |
| MDCK | EC50 |
0.7 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 after 24 hrs in presence of 100 uM verapamil
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 after 24 hrs in presence of 100 uM verapamil
|
[PMID: 17548493] |
| MDCK | EC50 |
2.67 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 at 1 mg/liter after 24 hrs
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 at 1 mg/liter after 24 hrs
|
[PMID: 17548493] |
| THP-1 | EC50 |
0.27 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 0.5 uM elacridar
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 0.5 uM elacridar
|
[PMID: 17548493] |
| THP-1 | EC50 |
0.31 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 100 uM verapamil
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 100 uM verapamil
|
[PMID: 17548493] |
| THP-1 | EC50 |
1.14 mg/L
Compound: Daptomycin
|
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs
Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs
|
[PMID: 17548493] |
Daptomycin has excellent in-vitro inhibitory and bactericidal activity against nafcillin-susceptible and resistant staphylococci (MIC90 less than or equal to 0.5 mg/L) and against enterococci (MIC90 less than or equal to 2.0 mg/L). Daptomycin is more active than vancomycin against the majority of isolated tested. With the exception of trimethoprim-sulphamethoxazole, daptomycin is the most active agent in vitro against enterococci, and is the most active against nafcillin-resistant staphylococci. Daptomycin and vancomycin show a marked increase in MIC when the inoculum is increased from 105 to 107 cfu/mL[1]. Daptomycin is effective within a very narrow range of drug concentrations (from 0.125 to 2.0 tLg/mL) and is more active than other agents tested against S. faecalis[2]. Daptomycin inhibits the formation of these nucleotide-linked intermediates[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 103060-53-3
-
Appearance Solid
-
Molecular Weight 1620.67
-
Formula C72H101N17O26
-
Color Off-white to light yellow
-
Synonyms
LY146032
-
Sequence
Dec-Trp-{d-Asn}-Asp-Thr-Gly-{Orn}-Asp-{d-Ala}-Asp-Gly-{d-Ser(Me)}-Glu-{Kynurenine} (Lactone: Thr4-Kynurenine13)
-
Sequence Shortening
Dec-W-{d-Asn}-DTG-{Orn}-D-{d-Ala}-DG-{d-Ser(Me)}-E-{Kynurenine} (Lactone: Thr4-Kynurenine13)
-
Structure Classification
-
Initial Source
soil actinomycete
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Virulence
Bactericidal and anti-quorum sensing activity of repurposing drug Visomitin against Staphylococcus aureus. [Abstract]2024 Dec;15(1):2415952. PMID: 39390774 -
mBio
Effect of antibiotics on Kupffer cell immunometabolism relative to intracellular killing of S. aureus using NAD(P)H fluorescence lifetime imaging. [Abstract]2025 Sep 30:e0212425. PMID: 41025812
Daptomycin purchased from MedChemExpress. Usage Cited in: mBio. 2025 Sep 30:e0212425. [Abstract]
Kupffer cell metabolism upon Daptomycin exposure in the absence of infection. KCs were treated with antibiotics at reported human Cmax concentrations for 10 h. M1 (Il6, Tnf, and Nos2) and M2 (Il10 and Arg1) polarization, as well as metabolic genes (Irg1, Hif1α, and Sdhb) were assessed by RT-qPCR.
Daptomycin purchased from MedChemExpress. Usage Cited in: mBio. 2025 Sep 30:e0212425. [Abstract]
Kupffer cell metabolism upon Daptomycin exposure in the absence of infection. NAD(P)H fluorescence lifetime was determined by TPE-FLIM.
Daptomycin purchased from MedChemExpress. Usage Cited in: mBio. 2025 Sep 30:e0212425. [Abstract]
Kupffer cell metabolism upon Daptomycin exposure in the absence of infection. Fluorescence decay curves from generated NAD(P)H data acquired by TPE-FLIM from each region of interest were fitted to a biexponential decay function and exported to ImageJ for single-cell NAD(P)H lifetime analysis. Spatial NAD(P)H lifetime data were further processed, then overlaid with associated transmitted light images to generate representative FLIM images for each treatment group.
-
Antimicrob Agents Chemother
Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis. [Abstract]2021 Jan 20;65(2):e01275-20. PMID: 33199387 -
ACS Omega
Antibacterial and Antibiofilm Activities of Sertindole and Its Antibacterial Mechanism against Staphylococcus aureus. [Abstract]2023 Feb 3;8(6):5415-5425. PMID: 36816695 -
ACS Omega
Lapatinib Acts against Biofilm Formation and the Hemolytic Activity of Staphylococcus aureus. [Abstract]2022 Mar 3;7(10):9004-9014. PMID: 35309438 -
Appl Microbiol Biotechnol
2022 Apr;106(7):2689-2702. PMID: 35338386 -
Microorganisms
Alanine Uptake Is Required to Maintain Staphylococcus aureus Cell Envelope Stability Under Magnesium and Calcium Limitation. [Abstract]2026 Jun 13;14(6):1332. PMID: 42354956 -
iScience
2022 Jan 5;25(2):103731. PMID: 35098100 -
Sci Rep
Genomic and phenotypic adaptations of methicillin resistant Staphylococcus aureus during vancomycin therapy. [Abstract]2025 May 2;15(1):15346. PMID: 40316685
Daptomycin purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 May 2;15(1):15346. [Abstract]
Population analysis profiles of MRSA isolates XF1 and XF2 in the presence of daptomycin.
-
Microbiol Spectr
In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin. [Abstract]2025 Oct 23:e0157625. PMID: 41128537
Daptomycin purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2025 Oct 23:e0157625. [Abstract]
Twenty-four-hour survival curves of six MRSA isolates and one MSSA isolate (STA 29213) at mid-exponential phase treated with steady-state concentrations of daptomycin (DAP, 0.5-1 mg/L). Each time point represents the mean values of the two replicates with standard deviations.
-
ACS Infect Dis
Derazantinib Inhibits the Planktonic Growth and Biofilm Formation of Staphylococcus aureus by Binding Membrane Phospholipids and Disrupting the Cell Membrane. [Abstract]2025 Jun 13;11(6):1473-1485. PMID: 40367508 -
ACS Infect Dis
Loratadine Derivative Lo-7: A Weapon against Drug-Resistant Enterococcus and Streptococcal Infections. [Abstract]2024 Aug 9;10(8):2961-2977. PMID: 39066703 -
ACS Infect Dis
Thiazolopyrimidinone Derivative H5-23 Enhances Daptomycin Activity against Linezolid-Resistant Enterococcus faecalis by Disrupting the Cell Membrane. [Abstract]2023 Dec 8;9(12):2523-2537. PMID: 38014911 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Infect Drug Resist
In Vitro Activity of Vancomycin, Teicoplanin, Linezolid and Daptomycin Against Methicillin-Resistant Staphylococcus aureus Isolates Collected from Chinese Hospitals in 2018-2020. [Abstract]2021 Dec 16;14:5449-5456. PMID: 34949928 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Int J Med Microbiol
In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin. [Abstract]2020 Jan;69(1):120-131. PMID: 31916929 -
Diagn Micr Infec Dis
In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci. [Abstract]2020 Jul;97(3):115040. PMID: 32354459 -
Pol J Microbiol
Mechanisms of Rapid Bactericidal and Anti-Biofilm Alpha-Mangostin In Vitro Activity against Staphylococcus aureus. [Abstract]2023 Jun 14;72(2):199-208. PMID: 37314356 -
-
-
-
Solvent & Solubility
H2O : 100 mg/mL (61.70 mM; Need ultrasonic)
DMSO : ≥ 100 mg/mL (61.70 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (1.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (61.70 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Protocol
Inocula containing 109 CFU/mL are prepared from an 18-h brain heart infusion broth culture. The exact number in each inoculum is subsequently determined by the standard serial 10-fold dilution agar pour plate technique. Animals are challenged intravenously with a 1.0-mL inoculum. This inoculum is known to infect the renal medulla of normal rats. Twenty-four hours later the animals are divided into eight groups and are given either saline only (controls) or antibiotic therapy initiated with Daptomycin at 10 mg/kg (Daptomycin10), Daptomycin at 20 mg/kg (Daptomycin20), Daptomycin10 plus gentamicin at 1.5 mg/kg, vancomycin at 20 mg/kg, vancomycin at 20 mg/kg plus gentamicin at 1.5 mg/kg, ampicillin at 30 mg per rat per injection, and ampicillin at 30 mg per rat plus gentamicin at 1.5 mg/kg. Animals receive Daptomycin20 once daily; all other drugs are administered twice daily. Vancomycin and Daptomycin are given subcutaneously; ampicillin and gentamicin are given intramuscularly. Drugs are administered for up to 13 days.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Benson CA, et al. Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against gram-positive organisms. J Antimicrob Chemother. 1987 Aug;20(2):191-6. [Content Brief]
[2]. Miniter PM, et al. Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob Agents Chemother. 1987 Aug;31(8):1199-203. [Content Brief]
[3]. Allen NE, et al. Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032. Antimicrob Agents Chemother. 1987 Jul;31(7):1093-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.6170 mL | 3.0851 mL | 6.1703 mL | 15.4257 mL |
| 5 mM | 0.1234 mL | 0.6170 mL | 1.2341 mL | 3.0851 mL | |
| 10 mM | 0.0617 mL | 0.3085 mL | 0.6170 mL | 1.5426 mL | |
| 15 mM | 0.0411 mL | 0.2057 mL | 0.4114 mL | 1.0284 mL | |
| 20 mM | 0.0309 mL | 0.1543 mL | 0.3085 mL | 0.7713 mL | |
| 25 mM | 0.0247 mL | 0.1234 mL | 0.2468 mL | 0.6170 mL | |
| 30 mM | 0.0206 mL | 0.1028 mL | 0.2057 mL | 0.5142 mL | |
| 40 mM | 0.0154 mL | 0.0771 mL | 0.1543 mL | 0.3856 mL | |
| 50 mM | 0.0123 mL | 0.0617 mL | 0.1234 mL | 0.3085 mL | |
| 60 mM | 0.0103 mL | 0.0514 mL | 0.1028 mL | 0.2571 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Daptomycin Related Classifications
HY-B0108 Related Classifications
Powered by Bioz